Birth Control Takes New Turn with Approval of Hormonal Ring

By Ritz, Jayne | Drug Topics, November 5, 2001 | Go to article overview

Birth Control Takes New Turn with Approval of Hormonal Ring


Ritz, Jayne, Drug Topics


Rx Care

New Drug

The effort to control unwanted pregnancies effectively and conveniently has turned a new page with the introduction of NuvaRing (Organon), a novel hormonal contraceptive vaginal device.

As the number of unwanted pregnancies is still on the rise in the United States, interest in curbing this growth is high. Pharmacists are in a leading position to assist patients in the selection of a contraceptive that takes into account the unique needs of each patient.

In clinical trials, all oral contraceptives are highly effective (> 99%) at preventing pregnancy if taken as prescribed. Unfortunately, actual pregnancy rates of 1% to 3% differ from those in clinical trials, primarily due to patient noncompliance. "Noncompliant patients who are currently taking an oral contraceptive pill may be more likely to experience breakthrough bleeding and possibly ovulation, which may lead to unwanted pregnancies," said Larry Seidman, D.O., clinical assistant professor, obstetrics and gynecology, MCP-Hahnemann School of Medicine in Philadelphia, a NuvaRing clinical investigator.

"For these patients, NuvaRing is a viable alternative hormonal contraception with increased convenience and protection," said Seidman. "Because the vaginal ring provides a month-long contraceptive protection, the patient does not have to remember to take a pill each day. The majority of the volunteers in the clinical study considered this new contraceptive method simple to use and were eager to inquire as to the eventual availability of the product."

Women can easily insert or remove the ring by pressing the sides of the circle together to gently push it into or remove it from the vagina. The correct positioning of the hoop is not critical because NuvaRing is not a barrier contraceptive. The small, flexible ethylene vinylacetate (EVA) ring is inserted on or before the fifth day of the menstrual period and designed to release a steady flow of low-dose etonogestrel-the biologically active metabolite of the progesterone desogestrel-and ethinyl estradiol (EE), the estrogen component (an average of 0.120 mg and 0.015 mg, respectively, per day) for over 21 days of use.

"Some of the noteworthy benefits of NuvaRing are the elimination of the first-pass effect with the attainment of steady-state blood levels of the hormones within three days of administration. Subsequently, this allows the use of the lowest effective dose with potentially lower adverse effects," noted Nancy Alexander, Ph.D., director of contraception medical services at Organon in West Orange, N. …

The rest of this article is only available to active members of Questia

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Birth Control Takes New Turn with Approval of Hormonal Ring
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Buy instant access to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    Buy instant access to save your work.

    Already a member? Log in now.

    Oops!

    An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.